Schrödinger Beheer

Beheer criteriumcontroles 4/4

De CEO Schrödinger is Ramy Farid, benoemd in Jan2008, heeft een ambtstermijn van 16.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.12M, bestaande uit 21.7% salaris en 78.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.25% van de aandelen van het bedrijf, ter waarde $ 3.49M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.1 jaar en 5.6 jaar.

Belangrijke informatie

Ramy Farid

Algemeen directeur

US$3.1m

Totale compensatie

Percentage CEO-salaris	21.7%
Dienstverband CEO	16.8yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	7.1yrs
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Jun 12

Recent updates

Schrödinger: Positive Signs Despite The Share Price Decline

Nov 21

Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 26% Higher

Nov 13

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Jun 12

Schrödinger: More Pharmaceutical Than Software

May 07

Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar

May 02

Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially

Mar 01

Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024

Mar 01

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Feb 28

The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%

Feb 01

Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable

Dec 18

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Sep 28

Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?

Jul 01

Schrödinger: Q2 Earnings Supports Growth Narrative

Aug 26

Schrödinger appoints Dr. Geoffrey Porges as finance chief

Aug 18

Sizing Up Schrodinger

Jun 06

Schrödinger: Holding The Keys To Discovery

Mar 26

Schrodinger: A Long-Term Hold For Biotech Investors With Upside Potential Too

Mar 15

Schrödinger: Conviction Remains High, Q4 Report And Guidance Will Be Critical

Jan 06

Analyse CEO-vergoeding

Hoe is Ramy Farid's beloning veranderd ten opzichte van Schrödinger's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$178m
Jun 30 2024	n/a	n/a	-US$201m
Mar 31 2024	n/a	n/a	-US$143m
Dec 31 2023	US$3m	US$677k	US$41m
Sep 30 2023	n/a	n/a	US$44m
Jun 30 2023	n/a	n/a	US$66m
Mar 31 2023	n/a	n/a	US$14m
Dec 31 2022	US$4m	US$651k	-US$149m
Sep 30 2022	n/a	n/a	-US$153m
Jun 30 2022	n/a	n/a	-US$148m
Mar 31 2022	n/a	n/a	-US$135m
Dec 31 2021	US$8m	US$620k	-US$100m
Sep 30 2021	n/a	n/a	-US$81m
Jun 30 2021	n/a	n/a	-US$42m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$9m	US$526k	-US$24m
Sep 30 2020	n/a	n/a	-US$20m
Jun 30 2020	n/a	n/a	-US$35m
Mar 31 2020	n/a	n/a	-US$33m
Dec 31 2019	US$633k	US$478k	-US$25m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$24m
Mar 31 2019	n/a	n/a	-US$29m
Dec 31 2018	US$1m	US$464k	-US$28m

Compensatie versus markt: De totale vergoeding ($USD 3.12M ) Ramy } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.38M ).

Compensatie versus inkomsten: De vergoeding van Ramy is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ramy Farid (59 yo)

16.8yrs

Tenure

US$3,124,165

Compensatie

Dr. Ramy Farid, Ph.D. is Independent Director of Vir Biotechnology, Inc. from May 29, 2024. He serves as the President of Schrödinger, Inc. since January 2008 and has been its Chief Executive Officer since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ramy Farid	CEO, President & Director	16.8yrs	US$3.12m	0.25% $ 3.5m
Richard Friesner	Co-Founder	34.3yrs	US$1.09m	1.69% $ 23.4m
Geoffrey Porges	Executive VP & CFO	2.3yrs	US$1.65m	0.0078% $ 107.6k
Robert Abel	Executive VP	less than a year	US$1.70m	0.0020% $ 27.0k
Karen Akinsanya	President of Research & Development Therapeutics	6.6yrs	US$1.68m	0% $ 0
Margaret Han Dugan	Chief Medical Officer	1.3yrs	US$3.46m	0.0031% $ 42.1k
William Goddard	Co-Founder & Scientific Advisor	no data	geen gegevens	geen gegevens
Kenneth Lorton	Executive VP	7.6yrs	US$4.49m	0.049% $ 680.2k
Shane Brauner	Executive VP & Chief Information Officer	7.8yrs	geen gegevens	geen gegevens
Jaren Madden	Senior Vice President of Investor Relations & Corporate Affairs	4.8yrs	geen gegevens	geen gegevens
Yvonne Tran	Corporate Secretary	14.8yrs	US$1.47m	0.0086% $ 118.8k
Mathew Halls	Senior Vice President of Materials Science	no data	geen gegevens	geen gegevens

7.1yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SDGR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ramy Farid	CEO, President & Director	11.9yrs	US$3.12m	0.25% $ 3.5m
Richard Friesner	Co-Founder	34.3yrs	US$1.09m	1.69% $ 23.4m
William Goddard	Co-Founder & Scientific Advisor	no data	geen gegevens	geen gegevens
Michael Lynton	Independent Chairman of the Board	6.8yrs	US$727.05k	0.0086% $ 118.3k
Gary Ginsberg	Independent Director	4.6yrs	US$689.55k	0.0086% $ 118.3k
Gary Sender	Independent Director	5.3yrs	US$707.05k	0.0086% $ 118.3k
Vijay Pande	Scientific Advisor	no data	geen gegevens	geen gegevens
William Jorgensen	Scientific Advisor	no data	geen gegevens	geen gegevens
Rosana Kapeller-Libermann	Independent Director	5.8yrs	US$687.05k	0.0086% $ 118.3k
Brian Shoichet	Scientific Advisor	no data	geen gegevens	geen gegevens
Nancy Thornberry	Independent Director	5.2yrs	US$684.55k	0.0086% $ 118.3k
Jeffrey Chodakewitz	Independent Director	4.6yrs	US$692.05k	0.0086% $ 118.3k

5.6yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SDGR wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

Schrödinger Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Schrödinger, Inc., Annual General Meeting, Jun 18, 2024

Executive VP & CTO notifies of intention to sell stock

Chief Legal & People Officer notifies of intention to sell stock

Independent Director exercised options and sold US$349k worth of stock

Insufficient new directors

Recent updates

Schrödinger: Positive Signs Despite The Share Price Decline

Schrödinger, Inc. Receives an Additional $9.5 Million from the Bill & Melinda Gates Foundation

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Schrödinger, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2024

Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 26% Higher

Schrödinger, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Schrödinger's Path Forward: AI, Cash Burn, And Clinical Uncertainty

Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues

Consensus EPS estimates upgraded to US$2.42 loss

Schrodinger: More Drug Discovery Validation

Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Schrödinger, Inc. Provides Earnings Guidance for the Third Quarter of 2024 and Fiscal Year Ending December 31, 2024

Schrödinger, Inc. to Report Q2, 2024 Results on Jul 31, 2024

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Schrödinger: More Pharmaceutical Than Software

Schrödinger, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Fiscal Year Ending December 31, 2024

New minor risk - Profitability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar

Schrödinger, Inc., Annual General Meeting, Jun 18, 2024

Schrödinger, Inc. to Report Q1, 2024 Results on May 01, 2024

Consensus revenue estimates fall by 18%

New minor risk - Share price stability

Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially

Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Investor sentiment improves as stock rises 18%

The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%

Price target decreased by 7.5% to US$43.67

Schrödinger, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable

Investor sentiment improves as stock rises 30%

Price target decreased by 14% to US$48.67

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 14% to US$48.67

Price target decreased by 7.0% to US$54.44

Schrödinger, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment deteriorates as stock falls 16%

Schrödinger, New York City College of Technology, and LaGuardia Community College Receives $1 Million Grant from the National Science Foundation to Increase Access to Computational Molecular Modeling Education

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Executive VP & CTO notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 23%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 8.4% to US$58.56

Chief Legal & People Officer notifies of intention to sell stock

Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?

Price target increased by 7.3% to US$55.56

New major risk - Revenue and earnings growth

Independent Director exercised options and sold US$349k worth of stock

Consensus EPS estimates increase from loss to US$0.394 profit

Schrödinger, Inc. Provides Earnings Guidance for the Second Quarter and Full Year Ending December 31, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

Insufficient new directors

Consensus EPS estimates upgraded to US$0.31 loss

Consensus EPS estimates fall by 21%

Price target decreased by 7.7% to US$51.38

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Executive VP exercised options and sold US$606k worth of stock

Schrödinger, Inc. to Report Q4, 2022 Results on Feb 28, 2023

CEO, President & Director exercised options and sold US$1.1m worth of stock

Forecast to breakeven in 2025

Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921

Price target decreased to US$61.00

Price target decreased to US$61.00

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.49 loss in 3Q 2021)

Schrödinger, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Schrödinger, Inc. to Report Q3, 2022 Results on Nov 03, 2022